Search Results - "Detke, Michael J."

A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia by Shen, Joan H.Q, Zhao, Yonggang, Rosenzweig-Lipson, Sharon, Popp, Danielle, Williams, Janet B.W, Giller, Earl, Detke, Michael J, Kane, John M

“…Abstract Vabicaserin, a potent 5-HT2C receptor agonist, decreases nucleus accumbens extracellular dopamine levels in rats, without affecting striatal dopamine,…”
Get full text

A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia by Chappell, Amy S, Bradley, Laurence A, Wiltse, Curtis, Detke, Michael J, D'Souza, Deborah N, Spaeth, Michael

“…Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six…”
Get full text

Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia by Mease, Philip J., MD, Russell, I. Jon, MD, Kajdasz, Daniel K., PhD, Wiltse, Curtis G., PhD, Detke, Michael J., MD, PhD, Wohlreich, Madelaine M., MD, Walker, Daniel J., PhD, Chappell, Amy S., MD

“…Objectives To assess the long-term safety, tolerability, and efficacy of duloxetine in patients with fibromyalgia. Methods We report results from the 6-month…”
Get full text

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram) by Mallinckrodt, Craig H, Prakash, Apurva, Houston, John P, Swindle, Ralph, Detke, Michael J, Fava, Maurizio

“…To test the hypothesis that in patients with major depressive disorder (MDD), the response for specific Hamilton Depression Rating Scale items will differ for…”
Get more information

Acute and Chronic Antidepressant Drug Treatment in the Rat Forced Swimming Test Model of Depression by Detke, Michael J, Johnson, Jennie, Lucki, Irwin

“…The forced swimming test (FST) is a widely used behavioral screen in rodents that is both sensitive and selective for clinically effective antidepressant…”
Get full text

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine by Trivedi, Madhukar H, Desaiah, Durisala, Ossanna, Melissa J, Pritchett, Yili L, Brannan, Stephen K, Detke, Michael J

“…Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine…”
Get full text

Duloxetine vs. placebo in patients with painful diabetic neuropathy by Goldstein, David J., Lu, Yili, Detke, Michael J., Lee, Thomas C., Iyengar, Smriti

“…The aim of this study was to examine the efficacy and safety of duloxetine, a balanced and potent dual reuptake inhibitor of serotonin and norepinephrine, in…”
Get full text

Duloxetine in the treatment of major depressive disorder: an open-label study by Hudson, James I, Perahia, David G, Gilaberte, Inmaculada, Wang, Fujun, Watkin, John G, Detke, Michael J

“…Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated…”
Get full text

Efficacy and safety of duloxetine in patients with chronic low back pain by Skljarevski, Vladimir, Desaiah, Durisala, Liu-Seifert, Hong, Zhang, Qi, Chappell, Amy S, Detke, Michael J, Iyengar, Smriti, Atkinson, Joseph H, Backonja, Miroslav

“…This was a randomized, double-blind, placebo-controlled clinical trial. To assess the efficacy and safety of duloxetine in the treatment of chronic low back…”
Get full text

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial by Russell, I. Jon, Mease, Philip J., Smith, Timothy R., Kajdasz, Daniel K., Wohlreich, Madelaine M., Detke, Michael J., Walker, Daniel J., Chappell, Amy S., Arnold, Lesley M.

“…The primary objectives of this study were to assess the efficacy and safety of duloxetine for reducing pain severity in fibromyalgia patients with or without…”
Get full text

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial by Rynn, Moira, Russell, James, Erickson, Janelle, Detke, Michael J., Ball, Susan, Dinkel, Jeff, Rickels, Karl, Raskin, Joel

“…Generalized anxiety disorder (GAD), a prevalent and chronic illness, is associated with dysregulation in both serotonergic and noradrenergic neurotransmission…”
Get full text

The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials by Mallinckrodt, Craig H, Raskin, Joel, Wohlreich, Madelaine M, Watkin, John G, Detke, Michael J

“…A mixed-effects model repeated measures approach (MMRM) was specified as the primary analysis in the Phase III clinical trials of duloxetine for the treatment…”
Get full text

Measures of outcome for stimulant trials: ACTTION recommendations and research agenda by Kiluk, Brian D, Carroll, Kathleen M, Duhig, Amy, Falk, Daniel E, Kampman, Kyle, Lai, Shengan, Litten, Raye Z, McCann, David J, Montoya, Ivan D, Preston, Kenzie L, Skolnick, Phil, Weisner, Constance, Woody, George, Chandler, Redonna, Detke, Michael J, Dunn, Kelly, Dworkin, Robert H, Fertig, Joanne, Gewandter, Jennifer, Moeller, F. Gerard, Ramey, Tatiana, Ryan, Megan, Silverman, Kenneth, Strain, Eric C

“…Highlights • Meaningful outcome measures, other than sustained abstinence, would be beneficial. • There are multiple challenges unique to measuring stimulant…”
Get full text

Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine by GOLDSTEIN, David J, YILI LU, DETKE, Michael J, WILTSE, Curtis, MALLINCKRODT, Craig, DEMITRACK, Mark A

“…Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major…”
Get full text

Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial by DETKE, Michael J, YILI LU, GOLDSTEIN, David J, HAYES, John R, DEMITRACK, Mark A

“…Despite treatment advances, major depressive disorder (MDD) is still a significant cause of morbidity and mortality. Current therapies frequently fall short of…”
Get full text

Efficacy of duloxetine and selective serotonin reuptake inhibitors : Comparisons as assessed by remission rates in patients with major depressive disorder by THASE, Michael E, LU PRITCHETT, Yili, OSSANNA, Melissa J, SWINDLE, Ralph W, XU, Jimmy, DETKE, Michael J

“…It has been proposed that serotonin and norepinephrine reuptake inhibitors (SNRIs) may result in higher remission rates of major depressive disorder than…”
Get full text

The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? by FAVA, Maurizio, MALLINCKRODT, Craig H, DETKE, Michael J, WATKIN, John G, WOHLREICH, Madelaine M

“…Depression is a chronic disease consisting of emotional/psychological and physical symptoms. Emotional symptoms have been shown to respond to currently…”
Get full text

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial by Detke, Michael J., Wiltse, Curtis G., Mallinckrodt, Craig H., McNamara, Robert K., Demitrack, Mark A., Bitter, Istvan

“…Background: Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE) that has previously been shown to be…”
Get full text

Comparison of Site-Based Versus Central Ratings in a Study of Generalized Anxiety Disorder by Williams, Janet B W, Kobak, Kenneth A, Giller, Earl, Reasner, David S, Curry, Lisa, Detke, Michael J

“…Lack of standardization across sites and raters, poor interrater reliability, and possible scoring bias affecting the primary outcome measure contribute to a…”
Get full text

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression by Detke, Michael J., Lu, Yili, Goldstein, David J., McNamara, Robert K., Demitrack, Mark A.

“…Existing therapies for major depressive disorder (MDD) have either limited efficacy and/or poor tolerability. The present study examined the effects of…”
Get full text